ClinicalTrials.gg
CompletedNCT05138653Updated Nov 26, 2024Results posted

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

A Phase 1 interventional study of CVL-354 and Placebo in Healthy Participants, sponsored by Cerevel Therapeutics, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a 2-part, double-blind, randomized, placebo-controlled, first-in-human trial evaluating a single ascending dose (4-way crossover, Part A) and multiple ascending doses (Part B) of CVL-354.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Volunteer
  • CVL-354
03

In context

Lead sponsor

Cerevel Therapeutics, LLC is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.

First submitted before Cerevel Therapeutics, LLC became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women of nonchildbearing potential and men 18 to 55 years, inclusive.
  2. Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, (ECG), vital sign measurements, and laboratory test results, as evaluated by the investigator.
  3. of 18.5 to 30.0 Kilograms per square meter (kg/m\^2), inclusive, and total body weight >50 Kilogram (kg) [110 Pound (lb)] at Screening.
  4. A male participant with a pregnant or a nonpregnant partner of must agree to use during the trial and 14 days following the last dose of study drug.
  5. Capable of giving signed
  6. Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine, hematological, immunological, or neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  2. Serious risk of suicide in the opinion of the Investigator
  3. History of substance or alcohol-use disorder (excluding nicotine or caffeine) within 12 months prior to signing the form (ICF).
  4. Any condition that could possibly affect drug absorption
  5. Receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccination or booster as follows:

    • messenger ribonucleic acid (mRNA): within 14 days prior to dosing
    • Non-mRNA: within 28 days prior to dosing In addition, participants who plan to receive SARS-CoV2 vaccination or booster while participating in the trial or for at least 14 days after the last dose of medicinal product (IMP) will be excluded.
  6. Have recently been diagnosed with symptomatic corona virus disease-2019 (COVID-19) or test positive for COVID-19 within 30 days prior to signing the ICF.
  7. Use of prohibited medication prior to randomization or likely to require prohibited concomitant therapy (eg, prescription and over-the-counter medications, herbal medications, vitamins, and supplements) during the trial
  8. Either of the following:

    • History of human immunodeficiency viruses (), , or infection
    • Positive result for HIV antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody
  9. Positive drug screen (including nicotine) or a positive test for alcohol
  10. Abnormal clinical laboratory test results or vital measurements at Screening and Check-in
  11. Estimated at Screening \<90 millilitre/minute/1.73m\^2 (mL/min/1.73 m\^2), as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  12. Abnormal 12-lead at Screening or initial Check-In (Day -1).
  13. Known allergy or to the IMP, closely related compounds, or any of their specified ingredients.
  14. Current enrollment or past participation within 30 days or 5 half-lives (whichever is longer) prior to signing the ICF in any other clinical trial involving an IMP.
  15. Any other abnormal safety findings unless, based on the investigator's judgment, the findings are not medically significant and would not impact the safety of the participant or the interpretation of the trial results.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1: Sequence 1

    Participants were randomized to sequence 1 to receive placebo on Day 1 of Period 1 followed by CVL-354 1.5 milligrams (mg) on Day 1 of Period 2, followed by CVL-354 5 mg on Day 1 of Period 3 \& followed by CVL-354 15 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 1: Sequence 2

    Participants were randomized to sequence 2 to receive CVL-354 0.5 mg on Day 1 of Period 1 followed by placebo on Day 1 of Period 2, followed by CVL-354 5 mg on Day 1 of Period 3 \& followed by CVL-354 15 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 1: Sequence 3

    Participants were randomized to sequence 3 to receive CVL-354 0.5 mg on Day 1 of Period 1 followed by CVL-354 1.5 mg on Day 1 of Period 2, followed by placebo on Day 1 of Period 3 \& followed by CVL-354 15 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 1: Sequence 4

    Participants were randomized to sequence 4 to receive CVL-354 0.5 mg on Day 1 of Period 1 followed by CVL-354 1.5 mg on Day 1 of Period 2, followed by CVL-354 5 mg on Day 1 of Period 3 \& followed by placebo on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 2: Sequence 1

    Participants were randomized to sequence 1 to receive placebo on Day 1 of Period 1 followed by CVL-354 90 mg on Day 1 of Period 2, followed by CVL-354 150 mg on Day 1 of Period 3 \& followed by CVL-354 200 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 2: Sequence 2

    Participants were randomized to sequence 2 to receive CVL-354 45 mg on Day 1 of Period 1 followed by placebo on Day 1 of Period 2, followed by CVL-354 150 mg on Day 1 of Period 3 \& followed by CVL-354 200 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 2: Sequence 3

    Participants were randomized to sequence 3 to receive CVL-354 45 mg on Day 1 of Period 1 followed by CVL-354 on 90 mg Day 1 of Period 2, followed by placebo on Day 1 of Period 3 \& followed by CVL-354 200 mg on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 2: Sequence 4

    Participants were randomized to sequence 4 to receive CVL-354 45 mg on Day 1 of Period 1 followed by CVL-354 90 mg on Day 1 of Period 2, followed by CVL-354 150 mg on Day 1 of Period 3 \& placebo on Day 1 of Period 4. Each dosing period was separated by a washout period of at least 5 days.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part A: Cohort 3: Sequence 1: Fed/Fasted Sequence

    Participants first received a single oral dose of CVL-354 50 mg, under fed state on Day 1 of Period 1 followed by a single oral dose of CVL-354 50 mg under fasted state on Day 1 of Period 2, with a washout period of 2 days between both periods.

    Drug: CVL-354

  • Experimental
    Part A: Cohort 3: Sequence 2: Fasted/Fed Sequence

    Participants first received a single oral dose of CVL-354 50 mg, under fasted state on Day 1 of Period 1 followed by a single oral dose of CVL-354 50 mg under fed state on Day 1 of Period 2, with a washout period of 2 days between both periods

    Drug: CVL-354

  • Experimental
    Part B: Cohort 1: CVL-354 10 mg

    Participants received oral dose of CVL-354 10 mg or Placebo, once daily (QD) from Day 1 up to Day 14 in Cohort 1.

    Drug: CVL-354 · Drug: Placebo

  • Experimental
    Part B: Cohort 2: CVL-354 25 mg

    Participants received oral dose of CVL-354 25 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 2.

    Drug: Placebo · Drug: CVL-354

  • Experimental
    Part B: Cohort 3: CVL-354 50 mg

    Participants received oral dose of CVL-354 50 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 3.

    Drug: Placebo · Drug: CVL-354

  • Experimental
    Part B: Cohort 4: CVL-354 80 mg

    Participants received oral dose of CVL-354 80 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 4.

    Drug: Placebo · Drug: CVL-354

  • Experimental
    Part B: Cohort 5: CVL-354 85 mg

    Participants received oral dose of CVL-354 85 mg or Placebo, QD from Day 1 up to Day 14 in Cohort 5.

    Drug: Placebo · Drug: CVL-354

Interventions

  • Oral solution/suspension

  • DrugPlacebo

    Placebo matched to CVL-354

  • Capsule

06

What researchers measure

Primary outcomes

  1. Part A: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial treatment, whether or not considered related to the trial treatment. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Adverse event which was reported to have started on Day 1 with no associated onset time were defined as TEAEs. TEAEs included both serious and non-serious TEAEs.

    Time frame: From the first dose of study drug up to end of follow-up period (Up to 72 days)

  2. Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    ECG parameters were assessed using continuous ECG recordings and standard 12-lead ECGs. The parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals, PR intervals, corrected QT (QTc) intervals, corrected QT with Bazett formula (QTcB), and corrected QT with Fredericia (QTcF) parameters measurement. Clinical significance of changes in ECG parameters was based on investigator's interpretation. Number of participants with clinically significant changes in ECG were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 72 days)

  3. Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Sign Measurements

    Vital signs include systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature. Clinical significance of changes in vital signs measurements was based on investigator's interpretation. Number of participants with clinically significant changes in vital signs were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 72 days)

  4. Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Laboratory parameters included blood chemistry, hematology, and urinalysis. Clinical significance of changes in laboratory parameters was based on investigator's interpretation. Number of participants with clinically significant changes in laboratory parameters (included hematology, blood chemistry, and urinalysis) were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 72 days)

  5. Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations

    The full physical examination included a review of the following body systems: head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, and musculoskeletal systems. The full neurological examination included an assessment of the participant's mental status (level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle appearance, tone, strength and reflexes), sensation (including Romberg sign), coordination, and gait. Clinical significance in changes of physical and neurological examination results were based on investigator's interpretation. Number of participants with clinically significant changes in physical and neurological examinations were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 72 days)

  6. Part A: Cohorts 1 and 2: Number of Participants With Changes in Suicidal Ideation or Suicidal Behavior Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)

    The C-SSRS is comprised of 10 categories with binary responses. The 10 categories include: Category 1 - Wish to be Dead; Category 2 - Non-specific Active Suicidal Thoughts; Category 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Category 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Category 5 - Active Suicidal Ideation with Specific Plan and Intent; Category 6 - Preparatory Acts or Behavior; Category 7 - Aborted Attempt; Category 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); Category 10 - Completed Suicide. Categories 1-5 represent Suicidal Ideation and categories 6-10 represent Suicidal Behavior. Each category is scored as 1 if there is a positive response in the category and a 0 if there are no positive responses in the category.

    Time frame: From the first dose of study drug up to end of treatment (Up to 72 days)

  7. Part A: Cohort 3: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial treatment, whether or not considered related to the trial treatment. A SAE was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Adverse event which was reported to have started on Day 1 with no associated onset time were defined as TEAEs. TEAEs included both serious and non-serious TEAEs.

    Time frame: From the first dose of study drug up to end of follow up period (Up to 22 days)

  8. Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in ECG Parameters

    ECG parameters were assessed using continuous ECG recordings and standard 12-lead ECGs. The parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals, PR intervals, corrected QT (QTc) intervals, corrected QT with Bazett formula (QTcB), and corrected QT with Fredericia (QTcF) parameters measurement. Clinical significance of changes in ECG parameters was based on investigator's interpretation. Number of participants with clinically significant changes in ECG were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 22 days)

  9. Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in Vital Sign Measurements

    Vital signs include systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature. Clinical significance of changes in vital signs measurements was based on investigator's interpretation. Number of participants with clinically significant changes in vital signs were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 22 days)

  10. Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Laboratory parameters included blood chemistry, hematology, and urinalysis. Clinical significance of changes in laboratory parameters was based on investigator's interpretation. Number of participants with clinically significant changes in laboratory parameters (included hematology, blood chemistry, and urinalysis) were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 22 days)

  11. Part A: Cohort 3: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations

    The full physical examination included a review of the following body systems: head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, and musculoskeletal systems. The full neurological examination included an assessment of the participant's mental status (level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle appearance, tone, strength and reflexes), sensation (including Romberg sign), coordination, and gait. Clinical significance in changes of physical and neurological examination results were based on investigator's interpretation. Number of participants with clinically significant changes in physical and neurological examinations were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 22 days)

  12. Part A: Cohort 3: Number of Participants With Changes in C-SSRS

    The C-SSRS is comprised of 10 categories with binary responses. The 10 categories include: Category 1 - Wish to be Dead; Category 2 - Non-specific Active Suicidal Thoughts; Category 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Category 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Category 5 - Active Suicidal Ideation with Specific Plan and Intent; Category 6 - Preparatory Acts or Behavior; Category 7 - Aborted Attempt; Category 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); Category 10 - Completed Suicide. Categories 1-5 represent Suicidal Ideation and categories 6-10 represent Suicidal Behavior. Each category is scored as 1 if there is a positive response in the category and a 0 if there are no positive responses in the category.

    Time frame: From the first dose of study drug up to end of treatment (Up to 22 days)

  13. Part B: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial treatment, whether or not considered related to the trial treatment. A SAE was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Adverse event which was reported to have started on Day 1 with no associated onset time were defined as TEAEs. TEAEs included both serious and non-serious TEAEs.

    Time frame: From the first dose of study drug up to end of follow up period (Up to 31 days)

  14. Part B: Number of Participants With Clinically Significant Changes in ECG Parameters

    ECG parameters were assessed using continuous ECG recordings and standard 12-lead ECGs. The parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals, PR intervals, corrected QT (QTc) intervals, corrected QT with Bazett formula (QTcB), and corrected QT with Fredericia (QTcF) parameters measurement. Clinical significance of changes in ECG parameters was based on investigator's interpretation. Number of participants with clinically significant changes in ECG were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 31 days)

  15. Part B: Number of Participants With Clinically Significant Changes in Vital Sign Measurements

    Vital signs include systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature. Clinical significance of changes in vital signs measurements was based on investigator's interpretation. Number of participants with clinically significant changes in vital signs were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 31 days)

  16. Part B: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

    Laboratory parameters included blood chemistry, hematology, and urinalysis. Clinical significance of changes in laboratory parameters was based on investigator's interpretation. Number of participants with clinically significant changes in laboratory parameters (included hematology, blood chemistry, and urinalysis) were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 31 days)

  17. Part B: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations

    The full physical examination included a review of the following body systems: head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, and musculoskeletal systems. The full neurological examination included an assessment of the participant's mental status (level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle appearance, tone, strength and reflexes), sensation (including Romberg sign), coordination, and gait. Clinical significance in changes of physical and neurological examination results were based on investigator's interpretation. Number of participants with clinically significant changes in physical and neurological examinations were reported.

    Time frame: From the first dose of study drug up to end of treatment (Up to 31 days)

  18. Part B: Number of Participants With Changes in C-SSRS

    The C-SSRS is comprised of 10 categories with binary responses. The 10 categories include: Category 1 - Wish to be Dead; Category 2 - Non-specific Active Suicidal Thoughts; Category 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Category 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Category 5 - Active Suicidal Ideation with Specific Plan and Intent; Category 6 - Preparatory Acts or Behavior; Category 7 - Aborted Attempt; Category 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); Category 10 - Completed Suicide. Categories 1-5 represent Suicidal Ideation and categories 6-10 represent Suicidal Behavior Each category is scored as 1 if there is a positive response in the category and a 0 if there are no positive responses in the category.

    Time frame: From the first dose of study drug up to end of treatment (Up to 31 days)

07

Results

Posted Nov 26, 2024

Participant flow

73 participants took part in the study at 1 investigative site in the United States of America from 18 October 2021 to 23 January 2023.

Single Ascending Dose (Up to 13 Weeks)
Participant flow — Single Ascending Dose (Up to 13 Weeks)
MilestonePart A: Cohort 1: Sequence 1Part A: Cohort 1: Sequence 2Part A: Cohort 1: Sequence 3Part A: Cohort 1: Sequence 4Part A: Cohort 2: Sequence 1Part A: Cohort 2: Sequence 2Part A: Cohort 2: Sequence 3Part A: Cohort 2: Sequence 4Part A: Cohort 3: Fed/Fasted SequencePart A: Cohort 3: Fasted/Fed SequencePart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Started2422323243000000
Completed1222222233000000
Not completed1200101010000000
Withdrew: Adverse event1000000000000000
Withdrew: Investigator's discretion0100000010000000
Withdrew: Withdrawal of consent0100100000000000
Withdrew: Other0000001000000000
Multiple Ascending Dose (Up to 12 Weeks)
Participant flow — Multiple Ascending Dose (Up to 12 Weeks)
MilestonePart A: Cohort 1: Sequence 1Part A: Cohort 1: Sequence 2Part A: Cohort 1: Sequence 3Part A: Cohort 1: Sequence 4Part A: Cohort 2: Sequence 1Part A: Cohort 2: Sequence 2Part A: Cohort 2: Sequence 3Part A: Cohort 2: Sequence 4Part A: Cohort 3: Fed/Fasted SequencePart A: Cohort 3: Fasted/Fed SequencePart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Started0000000000986788
Completed0000000000885677
Not completed0000000000101111
Withdrew: Adverse event0000000000101010
Withdrew: Withdrawal of consent0000000000000001
Withdrew: Disciplinary reason0000000000000100

Outcome measures

PrimaryPart A: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial treatment, whether or not considered related to the trial treatment. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Adverse event which was reported to have started on Day 1 with no associated onset time were defined as TEAEs. TEAEs included both serious and non-serious TEAEs.

Time frame:
From the first dose of study drug up to end of follow-up period (Up to 72 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPart A: Cohort 1 and 2: Pooled PlaceboPart A: Cohort 1: CVL-354 0.5 mgPart A: Cohort 1: CVL-354 1.5 mgPart A: Cohort 1: CVL-354 5 mgPart A: Cohort 1: CVL-354 15 mgPart A: Cohort 2: CVL-354 45 mgPart A: Cohort 2: CVL-354 90 mgPart A: Cohort 2: CVL-354 150 mgPart A: Cohort 2: CVL-354 200 mg
Part A: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)000101022
PrimaryPart A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters

ECG parameters were assessed using continuous ECG recordings and standard 12-lead ECGs. The parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals, PR intervals, corrected QT (QTc) intervals, corrected QT with Bazett formula (QTcB), and corrected QT with Fredericia (QTcF) parameters measurement. Clinical significance of changes in ECG parameters was based on investigator's interpretation. Number of participants with clinically significant changes in ECG were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 72 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
ParticipantsPart A: Cohort 1 and 2: Pooled PlaceboPart A: Cohort 1: CVL-354 0.5 mgPart A: Cohort 1: CVL-354 1.5 mgPart A: Cohort 1: CVL-354 5 mgPart A: Cohort 1: CVL-354 15 mgPart A: Cohort 2: CVL-354 45 mgPart A: Cohort 2: CVL-354 90 mgPart A: Cohort 2: CVL-354 150 mgPart A: Cohort 2: CVL-354 200 mg
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters000000000
PrimaryPart A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Sign Measurements

Vital signs include systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature. Clinical significance of changes in vital signs measurements was based on investigator's interpretation. Number of participants with clinically significant changes in vital signs were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 72 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Sign Measurements
ParticipantsPart A: Cohort 1 and 2: Pooled PlaceboPart A: Cohort 1: CVL-354 0.5 mgPart A: Cohort 1: CVL-354 1.5 mgPart A: Cohort 1: CVL-354 5 mgPart A: Cohort 1: CVL-354 15 mgPart A: Cohort 2: CVL-354 45 mgPart A: Cohort 2: CVL-354 90 mgPart A: Cohort 2: CVL-354 150 mgPart A: Cohort 2: CVL-354 200 mg
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Sign Measurements000000000
PrimaryPart A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Laboratory parameters included blood chemistry, hematology, and urinalysis. Clinical significance of changes in laboratory parameters was based on investigator's interpretation. Number of participants with clinically significant changes in laboratory parameters (included hematology, blood chemistry, and urinalysis) were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 72 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsPart A: Cohort 1 and 2: Pooled PlaceboPart A: Cohort 1: CVL-354 0.5 mgPart A: Cohort 1: CVL-354 1.5 mgPart A: Cohort 1: CVL-354 5 mgPart A: Cohort 1: CVL-354 15 mgPart A: Cohort 2: CVL-354 45 mgPart A: Cohort 2: CVL-354 90 mgPart A: Cohort 2: CVL-354 150 mgPart A: Cohort 2: CVL-354 200 mg
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters000000000
PrimaryPart A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations

The full physical examination included a review of the following body systems: head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, and musculoskeletal systems. The full neurological examination included an assessment of the participant's mental status (level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle appearance, tone, strength and reflexes), sensation (including Romberg sign), coordination, and gait. Clinical significance in changes of physical and neurological examination results were based on investigator's interpretation. Number of participants with clinically significant changes in physical and neurological examinations were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 72 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations
ParticipantsPart A: Cohort 1 and 2: Pooled PlaceboPart A: Cohort 1: CVL-354 0.5 mgPart A: Cohort 1: CVL-354 1.5 mgPart A: Cohort 1: CVL-354 5 mgPart A: Cohort 1: CVL-354 15 mgPart A: Cohort 2: CVL-354 45 mgPart A: Cohort 2: CVL-354 90 mgPart A: Cohort 2: CVL-354 150 mgPart A: Cohort 2: CVL-354 200 mg
Part A: Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations000000000
PrimaryPart A: Cohorts 1 and 2: Number of Participants With Changes in Suicidal Ideation or Suicidal Behavior Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)

The C-SSRS is comprised of 10 categories with binary responses. The 10 categories include: Category 1 - Wish to be Dead; Category 2 - Non-specific Active Suicidal Thoughts; Category 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Category 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Category 5 - Active Suicidal Ideation with Specific Plan and Intent; Category 6 - Preparatory Acts or Behavior; Category 7 - Aborted Attempt; Category 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); Category 10 - Completed Suicide. Categories 1-5 represent Suicidal Ideation and categories 6-10 represent Suicidal Behavior. Each category is scored as 1 if there is a positive response in the category and a 0 if there are no positive responses in the category.

Time frame:
From the first dose of study drug up to end of treatment (Up to 72 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 1 and 2: Number of Participants With Changes in Suicidal Ideation or Suicidal Behavior Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)
ParticipantsPart A: Cohort 1 and 2: Pooled PlaceboPart A: Cohort 1: CVL-354 0.5 mgPart A: Cohort 1: CVL-354 1.5 mgPart A: Cohort 1: CVL-354 5 mgPart A: Cohort 1: CVL-354 15 mgPart A: Cohort 2: CVL-354 45 mgPart A: Cohort 2: CVL-354 90 mgPart A: Cohort 2: CVL-354 150 mgPart A: Cohort 2: CVL-354 200 mg
Part A: Cohorts 1 and 2: Number of Participants With Changes in Suicidal Ideation or Suicidal Behavior Assessed Using the Columbia Suicide-Severity Rating Scale (C-SSRS)000000000
PrimaryPart A: Cohort 3: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial treatment, whether or not considered related to the trial treatment. A SAE was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Adverse event which was reported to have started on Day 1 with no associated onset time were defined as TEAEs. TEAEs included both serious and non-serious TEAEs.

Time frame:
From the first dose of study drug up to end of follow up period (Up to 22 days)
Reported as:
Count of participants · Participants
Part A: Cohort 3: Number of Participants With TEAEs
ParticipantsPart A: Cohort 3: Fed StatePart A: Cohort 3: Fasted State
Part A: Cohort 3: Number of Participants With TEAEs02
PrimaryPart A: Cohorts 3: Number of Participants With Clinically Significant Changes in ECG Parameters

ECG parameters were assessed using continuous ECG recordings and standard 12-lead ECGs. The parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals, PR intervals, corrected QT (QTc) intervals, corrected QT with Bazett formula (QTcB), and corrected QT with Fredericia (QTcF) parameters measurement. Clinical significance of changes in ECG parameters was based on investigator's interpretation. Number of participants with clinically significant changes in ECG were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 22 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in ECG Parameters
ParticipantsPart A: Cohort 3: Fed StatePart A: Cohort 3: Fasted State
Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in ECG Parameters00
PrimaryPart A: Cohorts 3: Number of Participants With Clinically Significant Changes in Vital Sign Measurements

Vital signs include systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature. Clinical significance of changes in vital signs measurements was based on investigator's interpretation. Number of participants with clinically significant changes in vital signs were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 22 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in Vital Sign Measurements
ParticipantsPart A: Cohort 3: Fed StatePart A: Cohort 3: Fasted State
Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in Vital Sign Measurements00
PrimaryPart A: Cohorts 3: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Laboratory parameters included blood chemistry, hematology, and urinalysis. Clinical significance of changes in laboratory parameters was based on investigator's interpretation. Number of participants with clinically significant changes in laboratory parameters (included hematology, blood chemistry, and urinalysis) were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 22 days)
Reported as:
Count of participants · Participants
Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsPart A: Cohort 3: Fed StatePart A: Cohort 3: Fasted State
Part A: Cohorts 3: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters00
PrimaryPart A: Cohort 3: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations

The full physical examination included a review of the following body systems: head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, and musculoskeletal systems. The full neurological examination included an assessment of the participant's mental status (level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle appearance, tone, strength and reflexes), sensation (including Romberg sign), coordination, and gait. Clinical significance in changes of physical and neurological examination results were based on investigator's interpretation. Number of participants with clinically significant changes in physical and neurological examinations were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 22 days)
Reported as:
Count of participants · Participants
Part A: Cohort 3: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations
ParticipantsPart A: Cohort 3: Fed StatePart A: Cohort 3: Fasted State
Part A: Cohort 3: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations00
PrimaryPart A: Cohort 3: Number of Participants With Changes in C-SSRS

The C-SSRS is comprised of 10 categories with binary responses. The 10 categories include: Category 1 - Wish to be Dead; Category 2 - Non-specific Active Suicidal Thoughts; Category 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Category 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Category 5 - Active Suicidal Ideation with Specific Plan and Intent; Category 6 - Preparatory Acts or Behavior; Category 7 - Aborted Attempt; Category 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); Category 10 - Completed Suicide. Categories 1-5 represent Suicidal Ideation and categories 6-10 represent Suicidal Behavior. Each category is scored as 1 if there is a positive response in the category and a 0 if there are no positive responses in the category.

Time frame:
From the first dose of study drug up to end of treatment (Up to 22 days)
Reported as:
Count of participants · Participants
Part A: Cohort 3: Number of Participants With Changes in C-SSRS
ParticipantsPart A: Cohort 3: Fed StatePart A: Cohort 3: Fasted Stated
Part A: Cohort 3: Number of Participants With Changes in C-SSRS00
PrimaryPart B: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial treatment, whether or not considered related to the trial treatment. A SAE was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Adverse event which was reported to have started on Day 1 with no associated onset time were defined as TEAEs. TEAEs included both serious and non-serious TEAEs.

Time frame:
From the first dose of study drug up to end of follow up period (Up to 31 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With TEAEs
ParticipantsPart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Part B: Number of Participants With TEAEs201223
PrimaryPart B: Number of Participants With Clinically Significant Changes in ECG Parameters

ECG parameters were assessed using continuous ECG recordings and standard 12-lead ECGs. The parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals, PR intervals, corrected QT (QTc) intervals, corrected QT with Bazett formula (QTcB), and corrected QT with Fredericia (QTcF) parameters measurement. Clinical significance of changes in ECG parameters was based on investigator's interpretation. Number of participants with clinically significant changes in ECG were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 31 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Clinically Significant Changes in ECG Parameters
ParticipantsPart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Part B: Number of Participants With Clinically Significant Changes in ECG Parameters000000
PrimaryPart B: Number of Participants With Clinically Significant Changes in Vital Sign Measurements

Vital signs include systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature. Clinical significance of changes in vital signs measurements was based on investigator's interpretation. Number of participants with clinically significant changes in vital signs were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 31 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Clinically Significant Changes in Vital Sign Measurements
ParticipantsPart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 2: CVL-354 50 mgPart B: Cohort 3: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Part B: Number of Participants With Clinically Significant Changes in Vital Sign Measurements000000
PrimaryPart B: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters

Laboratory parameters included blood chemistry, hematology, and urinalysis. Clinical significance of changes in laboratory parameters was based on investigator's interpretation. Number of participants with clinically significant changes in laboratory parameters (included hematology, blood chemistry, and urinalysis) were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 31 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
ParticipantsPart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Part B: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters000000
PrimaryPart B: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations

The full physical examination included a review of the following body systems: head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, and musculoskeletal systems. The full neurological examination included an assessment of the participant's mental status (level of consciousness, orientation, speech, memory, etc), cranial nerves, motor (muscle appearance, tone, strength and reflexes), sensation (including Romberg sign), coordination, and gait. Clinical significance in changes of physical and neurological examination results were based on investigator's interpretation. Number of participants with clinically significant changes in physical and neurological examinations were reported.

Time frame:
From the first dose of study drug up to end of treatment (Up to 31 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations
ParticipantsPart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Part B: Number of Participants With Clinically Significant Changes in Physical and Neurological Examinations000000
PrimaryPart B: Number of Participants With Changes in C-SSRS

The C-SSRS is comprised of 10 categories with binary responses. The 10 categories include: Category 1 - Wish to be Dead; Category 2 - Non-specific Active Suicidal Thoughts; Category 3 - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Category 4 - Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Category 5 - Active Suicidal Ideation with Specific Plan and Intent; Category 6 - Preparatory Acts or Behavior; Category 7 - Aborted Attempt; Category 8 - Interrupted Attempt; Category 9 - Actual Attempt (non-fatal); Category 10 - Completed Suicide. Categories 1-5 represent Suicidal Ideation and categories 6-10 represent Suicidal Behavior Each category is scored as 1 if there is a positive response in the category and a 0 if there are no positive responses in the category.

Time frame:
From the first dose of study drug up to end of treatment (Up to 31 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Changes in C-SSRS
ParticipantsPart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
Part B: Number of Participants With Changes in C-SSRS000000

Adverse events

Collected over Part A: Cohorts 1 and 2: From the first dose of study drug up to end of follow up period (Up to 72 days); Part A: Cohort 3: From the first dose of study drug up to end of follow up period (Up to 22 days); Part B: From the first dose of study drug up to end of follow up period (Up to 31 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Cohorts 1 and 2: Pooled Placebo0/16 (0%)0/16 (0%)0/16 (0%)
Part A: Cohort 1: CVL-354 0.5 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part A: Cohort 1: CVL-354 1.5 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part A: Cohort 1: CVL-354 5 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A: Cohort 1: CVL-354 15 mg0/5 (0%)0/5 (0%)0/5 (0%)
Part A: Cohort 2: CVL-354 45 mg0/5 (0%)0/5 (0%)1/5 (20%)
Part A: Cohort 2: CVL-354 90 mg0/4 (0%)0/4 (0%)0/4 (0%)
Part A: Cohort 2: CVL-354 150 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: Cohort 2: CVL-354 200 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: Cohort 3: Fed State0/7 (0%)0/7 (0%)0/7 (0%)
Part A: Cohort 3: Fasted State0/7 (0%)0/7 (0%)2/7 (28.6%)
Part B: Pooled Placebo0/9 (0%)0/9 (0%)2/9 (22.2%)
Part B: Cohort 1: CVL-354 10 mg0/8 (0%)0/8 (0%)0/8 (0%)
Part B: Cohort 2: CVL-354 25 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part B: Cohort 3: CVL-354 50 mg0/7 (0%)0/7 (0%)2/7 (28.6%)
Part B: Cohort 4: CVL-354 80 mg0/8 (0%)0/8 (0%)2/8 (25%)
Part B: Cohort 5: CVL-354 85 mg0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPart A: Cohorts 1 and 2: Pooled PlaceboPart A: Cohort 1: CVL-354 0.5 mgPart A: Cohort 1: CVL-354 1.5 mgPart A: Cohort 1: CVL-354 5 mgPart A: Cohort 1: CVL-354 15 mgPart A: Cohort 2: CVL-354 45 mgPart A: Cohort 2: CVL-354 90 mgPart A: Cohort 2: CVL-354 150 mgPart A: Cohort 2: CVL-354 200 mgPart A: Cohort 3: Fed StatePart A: Cohort 3: Fasted StatePart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mg
DiarrhoeaGastrointestinal disorders0/160/60/60/60/51/50/40/60/60/70/70/90/80/61/70/83/8
VomitingGastrointestinal disorders0/160/60/60/60/50/50/41/62/60/70/70/90/80/60/70/80/8
NauseaGastrointestinal disorders0/160/60/60/60/50/50/41/61/60/70/70/90/80/60/70/81/8
DizzinessNervous system disorders0/160/60/60/60/50/50/40/61/60/70/70/90/80/61/70/80/8
HeadacheNervous system disorders0/160/60/60/60/50/50/40/61/60/70/70/90/80/61/70/80/8
Coronavirus disease 2019 (COVID-19)Infections and infestations0/160/60/61/60/50/50/40/60/60/70/71/90/80/60/71/80/8
Product taste abnormalProduct Issues0/160/60/60/60/50/50/40/61/60/70/70/90/80/60/70/80/8
Alanine aminotransferase increasedInvestigations0/160/60/60/60/50/50/40/60/60/70/70/90/81/60/70/80/8
Feeling abnormalGeneral disorders0/160/60/60/60/50/50/40/60/60/71/70/90/80/60/70/80/8
Laryngitis viralInfections and infestations0/160/60/60/60/50/50/40/60/60/71/70/90/80/60/70/80/8

Baseline characteristics

Randomized Population included all participants who were randomized to investigational medicinal product (IMP).

Age, Categorical
Age, Categorical(Participants)Part A: Cohort 1: Sequence 1Part A: Cohort 1: Sequence 2Part A: Cohort 1: Sequence 3Part A: Cohort 1: Sequence 4Part A: Cohort 2: Sequence 1Part A: Cohort 2: Sequence 2Part A: Cohort 2: Sequence 3Part A: Cohort 2: Sequence 4Part A: Cohort 3: Fed/Fasted SequencePart A: Cohort 3: Fasted/Fed SequencePart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mgTotal
<=18 years00000000000000000
Between 18 and 65 years242232324398678873
>=65 years00000000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Cohort 1: Sequence 1Part A: Cohort 1: Sequence 2Part A: Cohort 1: Sequence 3Part A: Cohort 1: Sequence 4Part A: Cohort 2: Sequence 1Part A: Cohort 2: Sequence 2Part A: Cohort 2: Sequence 3Part A: Cohort 2: Sequence 4Part A: Cohort 3: Fed/Fasted SequencePart A: Cohort 3: Fasted/Fed SequencePart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mgTotal
Female01001000111000016
Male232222323288678767
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Cohort 1: Sequence 1Part A: Cohort 1: Sequence 2Part A: Cohort 1: Sequence 3Part A: Cohort 1: Sequence 4Part A: Cohort 2: Sequence 1Part A: Cohort 2: Sequence 2Part A: Cohort 2: Sequence 3Part A: Cohort 2: Sequence 4Part A: Cohort 3: Fed/Fasted SequencePart A: Cohort 3: Fasted/Fed SequencePart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mgTotal
Hispanic or Latino001030121113032119
Not Hispanic or Latino241202203285646754
Unknown or Not Reported00000000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Cohort 1: Sequence 1Part A: Cohort 1: Sequence 2Part A: Cohort 1: Sequence 3Part A: Cohort 1: Sequence 4Part A: Cohort 2: Sequence 1Part A: Cohort 2: Sequence 2Part A: Cohort 2: Sequence 3Part A: Cohort 2: Sequence 4Part A: Cohort 3: Fed/Fasted SequencePart A: Cohort 3: Fasted/Fed SequencePart B: Pooled PlaceboPart B: Cohort 1: CVL-354 10 mgPart B: Cohort 2: CVL-354 25 mgPart B: Cohort 3: CVL-354 50 mgPart B: Cohort 4: CVL-354 80 mgPart B: Cohort 5: CVL-354 85 mgTotal
American Indian or Alaska Native10000000000000001
Asian01000000000101014
Native Hawaiian or Other Pacific Islander00000000000000000
Black or African American121201112074525438
White011031212223143228
More than one race00000000010000012
Unknown or Not Reported00000000000000000
08

Study locations

1 site
  • Labcorp Drug Development
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jan 2023, 15 months.

Results were first posted in Nov 2024, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 1, 2021
StartActual
Oct 18, 2021
Primary completionActual
Jan 23, 2023
CompletionActual
Jan 23, 2023
Results first posted
Nov 26, 2024
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05138653
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Oct 18, 2021
Primary completion
Jan 23, 2023
Completion
Jan 23, 2023
Results posted
Nov 26, 2024
Last update
Nov 26, 2024

Study contacts

Matthew Leoni, MD, MBA
study director · Cerevel Therapeutics, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icalcaprant

Start the discussion